Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 2/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097240 | 0.83 | TP53 (0.44) | NOD2NOD1CCR2TP53ICMT | |
| SCHEMBL4940384 | 0.83 | MMP12 (0.44) | NOD2NOD1ALOX5APSERPINE1PPARG | |
| SCHEMBL5100318 | 0.80 | NOD2 (0.70) | NOD2NOD1CCR2GPR35MEN1 | |
| SCHEMBL5097220 | 0.79 | SRD5A2 (0.50) | NOD2NOD1ALOX5APMEN1KMT2A | |
| SCHEMBL5100158 | 0.76 | SERPINE1 (0.47) | ICMTSERPINE1GAAPTGES2PPARG | |
| SCHEMBL4944885 | 0.76 | SERPINE1 (0.50) | CCR2ALOX5APSERPINE1GAAPPARG | |
| SCHEMBL5100347 | 0.74 | ALDH1A1 (0.46) | CCR2GPR35GAAPPARG | |
| SCHEMBL5093653 | 0.70 | CCR9 (0.55) | CCR2TP53SERPINE1MEN1KMT2A | |
| SCHEMBL5100813 | 0.69 | SERPINE1 (0.59) | TP53ICMTSERPINE1PTGES2PPARG | |
| SCHEMBL5100968 | 0.69 | SRD5A2 (0.47) | ALOX5APTP53MEN1KMT2APPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459478-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| US-7101903-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1569639-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004052893-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AND 3-OXOACETIC ACID SUBSTITUTED 2-HYDROXYMETHYLINDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | FGB, SERPINE1, MMP1 | NOD2 3379/4885NOD1 880/4885CCR2 734/4885 |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F2 | NOD2 3636/4885NOD1 947/4885CCR2 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.